This proposal for a Cancer Center Support Grant (CCSG) requests funding to support the cancer research activities of the Kimmel Cancer Center (KCC), in order to increase the survival and quality of life of cancer patients by translating basi research discoveries into new strategies to prevent, diagnose, monitor and cure human cancer. The major thrust of the Kimmel Cancer Center is in discovery and translation of the latest findings in the genetics, cell biology, biochemistry and immunology of cancer into novel modalities to cure cancer. The Kimmel Cancer Center consists of six programs and ten shared resources to support the research programs. Investigators in each program are involved in intra-programmatic and inter-programmatic collaborations and have been extremely successful in obtaining peer-reviewed funding for these collaborative studies. The environment within the KCC has facilitated numerous collaborative studies and publications that have contributed to important advances in cancer research. The KCC programs are supported by $56.3 million in total peer-reviewed sponsored funding. Funding comes from NCI sponsored projects totals $23.3 million. The efforts of the Director and his recruits have resulted in increased philanthropic University and Hospital support. The importance of cancer research and care at Thomas Jefferson University is reflected in the Director's authority over clinical and research activities at the Institution, encompassing 196,936 sq. ft. which includes the Breast Center, Oncology Center and research space. These state of the art KCC facilities enhance the translational cancer research effort of the Kimmel Cancer Center. The KCC has included the Lankenau Institute of Medical Research as part of the endorsed Consortium Cancer Center since 2007. The current submission also includes Drexel University cancer researchers. The inclusion of Drexel University cancer researchers extends a long-standing history of collaborative research publications and grants between consortium investigators.
This grant supports the basic and clinical research activities of the Kimmel Cancer Center, whose mission is to perform outstanding basic research in cancer, translate these novel discoveries to patient care and improve the quality of life of our cancer patients and their loved ones.
|Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693|
|Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603|
|Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:|
|Waldman, Scott A; Camilleri, Michael (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67:1543-1552|
|Sullivan-Reed, Katherine; Bolton-Gillespie, Elisabeth; Dasgupta, Yashodhara et al. (2018) Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep 23:3127-3136|
|Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35|
|Lapadula, Dominic; Farias, Eduardo; Randolph, Clinita E et al. (2018) Effects of Oncogenic G?q and G?11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res :|
|Vite, Alexia; Zhang, Caimei; Yi, Roslyn et al. (2018) ?-Catenin-dependent cytoskeletal tension controls Yap activity in the heart. Development 145:|
|McNair, Christopher; Xu, Kexin; Mandigo, Amy C et al. (2018) Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest 128:341-358|
|Garcia, Samantha A; Lebrun, Aurore; Kean, Rhonda B et al. (2018) Clearance of attenuated rabies virus from brain tissues is required for long-term protection against CNS challenge with a pathogenic variant. J Neurovirol 24:606-615|
Showing the most recent 10 out of 807 publications